Scientific programm: Abstract

4th scientific session: Follow ups on Strategies

30. Adjuvant Intravitreal Bevacizumab in the
      Management of Eales' Disease

Paul B. Griggs (Seattle)

Objective: To review the efficacy of the adjuvant use of intravitreal bevacizumab in the management of Eales' disease.
Purpose: To review the efficacy of the adjuvant use of intravitreal bevacizumab in the management of Eales' disease.
Methods: An otherwise healthy 37 yo Indian male presented with a recent bilateral reduction in visual function. A complete ophthalmic evaluation was performed along with a targeted laboratory evaluation. Therapy was initiated based on the results of these evaluations.
Results: The initial clinical evaluation revealed evidence of a bilateral occlusive retinal vascular disorder with associated retinal neovascularization. A targeted laboratory evaluation was significant for a positive quantiferon determination. An infectious disease consult was obtained. Therapy with intravitreal bevacizumab followed by panretinal laser photocoagulation (PRP) treatment was initiated for both eyes. The response to therapy is presented.
Conclusion: Eales' disease is uncommon in clinical practice. The etiology of Eales' disease remains uncertain. As such, the optimal treatment algorithm for this disorder has yet to be determined. There is limited data regarding the use of intravitreal bevacizumab in the management of Eales' disease. Reported herein is the clinical response to the use of intravitreal bevacizumab with PRP in this condition.

Copyright © VRS-online, 1999-. All rights reserved. Impressum, rechtliche Hinweise
HTML & Webdesign: SPALLEK.COM